FDA Panel Endorses Booster for All J&J Recipients
VRBPAC declined to vote on booster doses given at least 6 months from the initial dose, stating that it would be unlikely any adverse events (AEs) would arise at 6 months, but not at 2 months, and that the 6-month data presented by the sponsor was only from 17 people. FDA conducted an independent assessment…